<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01148953</url>
  </required_header>
  <id_info>
    <org_study_id>ALN-TTR01-001</org_study_id>
    <secondary_id>2009-017383-16</secondary_id>
    <nct_id>NCT01148953</nct_id>
  </id_info>
  <brief_title>Trial to Evaluate Safety and Tolerability of ALN-TTR01 in Transthyretin (TTR) Amyloidosis</brief_title>
  <official_title>A Phase 1, Randomized, Single-Blind, Placebo-Controlled, Dose Escalation Trial to Evaluate the Safety and Tolerability of a Single Dose of Intravenous ALN-TTR01 in Patients With TTR Amyloidosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alnylam Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alnylam Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety, tolerability, pharmacokinetics and
      pharmacodynamics of a single dose of ALN-TTR01 in patients with transthyretin (TTR) mediated
      amyloidosis (ATTR).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The proportion of patients experiencing adverse events (AEs), serious adverse events (SAEs), and study drug discontinuation.</measure>
    <time_frame>Up to 28 Days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) of ALN-TTR01 (Cmax, tmax, t1/2, AUC0-last, CL)</measure>
    <time_frame>Up to 70 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of ALN-TTR01 on Circulating TTR Levels (Determination of % Lowering of TTR to Pretreatment/Baseline TTR Level)</measure>
    <time_frame>up to 70 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Transthyretin Mediated Amyloidosis (ATTR)</condition>
  <arm_group>
    <arm_group_label>ALN-TTR01</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sterile Normal Saline (0.9% NaCl)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ALN-TTR01</intervention_name>
    <description>Dose levels between 0.01 and 1.0 mg/kg by intravenous (IV) infusion</description>
    <arm_group_label>ALN-TTR01</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sterile Normal Saline (0.9% NaCl)</intervention_name>
    <description>Calculated volume to match active comparator</description>
    <arm_group_label>Sterile Normal Saline (0.9% NaCl)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of TTR amyloidosis

          -  Adequate blood counts, liver and renal function

          -  Women of child-bearing potential must have a negative pregnancy test, cannot be breast
             feeding, and must use an adequate method of birth control

          -  Males agree to use appropriate contraception

          -  Willing and able to comply with protocol-required visit schedule and visit
             requirements and provide written informed consent.

        Exclusion Criteria:

          -  Known human immunodeficiency virus (HIV) positive status

          -  Receiving antibiotics for bacterial infection within 7 days of screening

          -  Known or suspected systemic viral, parasitic or fungal infection

          -  Receiving an investigational agent within 30 days prior to study drug administration

          -  Poor cardiac function

          -  Considered unfit for the study by the Principal Investigator

          -  Known sensitivity to oligonucleotides

          -  Employee or family member of the sponsor or the clinical study site personnel.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jared Gollob, MD</last_name>
    <role>Study Director</role>
    <affiliation>Alnylam Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>Le Kremlin Bicêtre</city>
        <zip>94275</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>Porto</city>
        <zip>4099-001</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>Umeå</city>
        <zip>SE 901 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>London</city>
        <zip>SE1 1YR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Portugal</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 21, 2010</study_first_submitted>
  <study_first_submitted_qc>June 22, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 23, 2010</study_first_posted>
  <last_update_submitted>May 23, 2012</last_update_submitted>
  <last_update_submitted_qc>May 23, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 24, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amyloidosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

